company background image
IXC logo

Invex Therapeutics CHIA:IXC Stock Report

Last Price

AU$0.084

Market Cap

AU$5.0m

7D

0%

1Y

-64.3%

Updated

29 Nov, 2024

Data

Company Financials

IXC Stock Overview

A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. More details

IXC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends2/6

Invex Therapeutics Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invex Therapeutics
Historical stock prices
Current Share PriceAU$0.084
52 Week HighAU$0.26
52 Week LowAU$0.061
Beta0.41
11 Month Change0%
3 Month Changen/a
1 Year Change-64.26%
33 Year Change-87.27%
5 Year Change-88.00%
Change since IPO-91.60%

Recent News & Updates

Recent updates

Shareholder Returns

IXCAU PharmaceuticalsAU Market
7D0%4.9%1.5%
1Y-64.3%35.6%17.9%

Return vs Industry: IXC underperformed the Australian Pharmaceuticals industry which returned 35.6% over the past year.

Return vs Market: IXC underperformed the Australian Market which returned 17.9% over the past year.

Price Volatility

Is IXC's price volatile compared to industry and market?
IXC volatility
IXC Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement8.5%
10% most volatile stocks in AU Market17.3%
10% least volatile stocks in AU Market3.2%

Stable Share Price: IXC's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine IXC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2019n/an/awww.invextherapeutics.com

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

Invex Therapeutics Ltd Fundamentals Summary

How do Invex Therapeutics's earnings and revenue compare to its market cap?
IXC fundamental statistics
Market capAU$5.04m
Earnings (TTM)-AU$1.64m
Revenue (TTM)AU$1.21m

4.2x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IXC income statement (TTM)
RevenueAU$1.21m
Cost of RevenueAU$0
Gross ProfitAU$1.21m
Other ExpensesAU$2.85m
Earnings-AU$1.64m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.022
Gross Margin100.00%
Net Profit Margin-135.43%
Debt/Equity Ratio0%

How did IXC perform over the long term?

See historical performance and comparison

Dividends

221.8%

Current Dividend Yield

n/a

Payout Ratio